GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Hepatitis/HBV Reactivation During Immunosuppressive Therapy: Alimentary Pharmacology & Therapeutics | July 2026

HBV Reactivation During Immunosuppressive Therapy: Alimentary Pharmacology & Therapeutics | July 2026

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated July 1, 2026

Quick Answer

Introduction: Hepatitis B virus (HBV) reactivation remains a potentially serious complication of immunosuppressive and anticancer therapies. While current guidelines classify patients into high-, moderate-, and low-risk categories, this editorial discusses new real-world evidence suggesting that HBV reactivation risk is more dynamic than previously appreciated.


Introduction:

Hepatitis B virus (HBV) reactivation remains a potentially serious complication of immunosuppressive and anticancer therapies. While current guidelines classify patients into high-, moderate-, and low-risk categories, this editorial discusses new real-world evidence suggesting that HBV reactivation risk is more dynamic than previously appreciated.

Key Takeaways:

  • Current HBV risk stratification remains broadly valid, with anti-CD20 therapies continuing to carry the highest risk of HBV reactivation.
  • Clinically meaningful HBV reactivation can still occur in patients considered "low risk," particularly those receiving low-dose or short-term corticosteroids.
  • HBV risk is dynamic rather than binary, influenced by cumulative immunosuppression, combination therapies, host factors, and monitoring intensity.
  • Tyrosine kinase inhibitors, anthracyclines, and several targeted therapies also demonstrated clinically relevant HBV reactivation risk.
  • Even with regular HBV DNA monitoring, some patients progressed to hepatitis, highlighting the limitations of surveillance alone.
  • The findings renew the debate over HBV DNA monitoring versus universal antiviral prophylaxis, especially in patients receiving prolonged or multidrug immunosuppressive therapy.
  • Treatment decisions should consider the overall immunosuppressive burden rather than relying solely on individual drug-risk categories.

Clinical Impact:

This editorial reinforces current guideline recommendations while emphasizing that "low risk" should never be interpreted as "no risk." Careful HBV screening, individualized risk assessment, close monitoring, and timely antiviral prophylaxis remain essential for patients receiving immunosuppressive therapy.

Bottom Line:

HBV reactivation risk exists across the entire spectrum of immunosuppressive therapy. Rather than depending solely on static drug-based categories, clinicians should adopt a dynamic, patient-centered approach that accounts for cumulative immunosuppression and individual risk factors.

Related Q&A

A Steroid-Sparing Breakthrough(Obexelimab) for IgG4-Related Disease: NEJM | June 2026

Introduction: IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder that can affect virtually any organ. Although glucocorticoids remain the mainstay of treatment, relapse is common after tapering, and long-term steroid toxicity remains a major concern....

Advancing Liver Health in a Shifting Global Landscape: Nat Re Gastro & Hepatol | July 2026

Introduction: Liver disease is entering a new era. While steatotic liver disease (SLD) is rapidly becoming one of the world's leading non-communicable diseases, progress toward viral hepatitis elimination has slowed. This editorial highlights the urgent...

ML Predicts Response to TPE in Pediatric ALF: JCEH | July 2026

Introduction: Therapeutic plasma exchange (TPE) is increasingly used in pediatric acute liver failure (ALF), but it artificially lowers bilirubin and INR, making it difficult to determine whether a child is truly improving or requires urgent...

Alcohol Intake and Health Study: J of Studies on Alcohol and Drugs | July 2026

Introduction: For decades, low-to-moderate alcohol consumption has been considered by some to offer potential cardiovascular benefits. This comprehensive U.S. modeling study re-evaluated the lifetime health impact of alcohol consumption using contemporary cause-specific data on alcohol-related...

Genetic Testing in Adult Cholestatic Liver Disease: Gut | June 2026

Introduction: Advances in genetic sequencing have transformed the understanding of cholestatic liver diseases. Conditions once considered exclusive to children are now recognized in adolescents and adults, with genetic variants increasingly explaining unexplained cholestasis, recurrent pruritus,...

Genetic Testing in Adult Cholestatic Liver Disease: Gut | July 2026

Introduction: Advances in genetic sequencing have transformed the understanding of cholestatic liver diseases. Conditions once considered exclusive to children are now recognized in adolescents and adults, with genetic variants increasingly explaining unexplained cholestasis, recurrent pruritus,...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer